[
    [
        {
            "time": "2019-10-21",
            "original_text": "格隆汇港股聚焦(10.21)︱中国移动前三季纯利跌14%至818亿元 石四药集团前三季纯利升17.2%至7.59亿港元",
            "features": {
                "keywords": [
                    "中国移动",
                    "纯利",
                    "下跌",
                    "石四药集团",
                    "纯利",
                    "上升"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "电信",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(10.21)︱中国移动前三季纯利跌14%至818亿元 石四药集团前三季纯利升17.2%至7.59亿港元",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-10-21",
            "original_text": "复星医药(600196.SH)：朝晖药业获药品GMP证书",
            "features": {
                "keywords": [
                    "复星医药",
                    "朝晖药业",
                    "GMP证书"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)：朝晖药业获药品GMP证书",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-10-21",
            "original_text": "如何看待骨科企业股价屡创新高？",
            "features": {
                "keywords": [
                    "骨科企业",
                    "股价",
                    "创新高"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "如何看待骨科企业股价屡创新高？",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-10-21",
            "original_text": "8省确定“4＋7”扩围时间，药企开始加速创新升级",
            "features": {
                "keywords": [
                    "4+7扩围",
                    "药企",
                    "创新升级"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "8省确定“4＋7”扩围时间，药企开始加速创新升级",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-10-21",
            "original_text": "石药集团(01093)、石四药集团(02005)、中国旭阳集团(01907)、21世纪教育(01598)实地调研",
            "features": {
                "keywords": [
                    "石药集团",
                    "石四药集团",
                    "中国旭阳集团",
                    "21世纪教育",
                    "实地调研"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "化工",
                    "教育"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "石药集团(01093)、石四药集团(02005)、中国旭阳集团(01907)、21世纪教育(01598)实地调研",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-10-02",
            "original_text": "智通港股通持股分析|10月2日",
            "features": {
                "keywords": [
                    "港股通",
                    "持股分析"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智通港股通持股分析|10月2日",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        }
    ]
]